A groundbreaking study published in PLOS Biology (February 19, 2026) demonstrates that metabolic modeling can predict probiotic engraftment and microbiota-mediated short-chain fatty acid (SCFA) production in response to probiotic and prebiotic interventions.
Researchers leveraged microbial community-scale metabolic models (MCMMs) using data from human clinical trial cohorts testing a five-strain probiotic combined with prebiotic inulin to improve metabolic health and an eight-strain probiotic to treat recurrent Clostridioides difficile infections. The models achieved 75%-80% accuracy in predicting engraftment.
MCMMs captured treatment-driven shifts in predicted SCFA production, and higher model-predicted growth rates of Akkermansia muciniphila were negatively associated with glucose area under the curve (AUC), providing clues about the mechanisms underlying treatment efficacy. Extending these models to a third human cohort revealed substantial inter-individual variability in predicted responses to increasing dietary fiber, which were significantly associated with baseline-to-follow-up changes in cardiometabolic health markers.
The study concludes that personalized prebiotic selection may further enhance probiotic efficacy, demonstrating the potential of metabolic modeling to guide personalized microbiome-mediated interventions.
Growth in the probiotics market is strongly supported by advances in encapsulation and stabilization technologies. Less processed food and nutrition industries are increasingly adopting microencapsulation and nanoencapsulation to improve ingredient performance, shelf life, and bioavailability.
One of the most dynamic frontiers for probiotics in 2026 is the gut-brain axis, where the field of psychobiotics continues to expand. Research has shown that gut bacteria can influence neurotransmitter production, stress response, and cognitive performance, laying the groundwork for probiotic solutions that target mood, focus, and resilience.
The probiotics for pets market is experiencing rapid growth. According to market research, the market was valued at USD 625.38 million in 2025 and is projected to reach USD 713.95 million in 2026, growing at a CAGR of 14.87%.
A groundbreaking study published in PLOS Biology (February 19, 2026) demonstrates that metabolic modeling can predict probiotic engraftment and microbiota-mediated short-chain fatty acid (SCFA) production in response to probiotic and prebiotic interventions.
The infant and kids’ probiotics market continues to expand with new formulations designed for immunity, digestive balance, and early-life microbiome development. Valued at approximately $5.1 billion in 2025, this segment is experiencing strong double-digit growth as parents increasingly prioritize preventive solutions backed by clinical research.
The International Society of Sports Nutrition (ISSN) has released its Position Stand on probiotics for athletes, providing an authoritative review of the mechanisms and use of probiotic supplementation to optimize the health, performance, and recovery of athletes. The position stand concludes that probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits on the host.
Women’s health is one of the fastest-growing probiotic applications. According to Future Market Insights, the women’s probiotic market, valued at roughly $1.8 billion in 2025, is projected to grow nearly 18% annually through 2035, reaching close to $9.6 billion. This momentum reflects growing consumer understanding of the microbiome’s importance in vaginal health, urinary health, and menopausal comfort.
Gut health innovation moved into a new phase of maturity in 2025. No longer solely driven by live microbial counts or broad probiotic positioning, brands and manufacturers are now relying on more precise ingredient classes such as postbiotics, structured fibers, standardized fermentates, and defined metabolites.
The global probiotics market is entering a new phase of structurally strong growth. According to MarketsandMarkets, the market was valued at USD 76.59 billion in 2025 and is projected to reach USD 114.95 billion by 2030, growing at a CAGR of 8.5% during the forecast period. This expansion reflects a fundamental shift in consumer behavior toward long-term wellness and preventive nutrition.
We are excited to announce that Minsheng Zhongke-Jiayi Probiotics will be exhibiting at Vitafoods Europe 2026 – the world’s leading event for nutraceutical, functional food, and supplement ingredients.
Copyright © 2025 by Minsheng Zhongke-Jiayi (Shandong) Bioengineering Co., Ltd. All Rights Reserved
Privacy Policy
